Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades

Stock Track

05/06

Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.

The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.

The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1155955988"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155955988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155955988?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155955988","market":"us","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades","media":"Stock Track","content":"<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1155955988","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155955988","pubTimestamp":1778079731,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"个股追踪|Veracyte盘中飙升17.77%，因Q1盈利强劲、指引上调和分析师升级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}